Proton Pump Inhibitor Market Global Insights

Proton pump inhibitor market was valued at USD 3.3 billion in 2023 and is expected to reach 4.12 billion by 2028, with a compound annual growth rate (CAGR) of 4.5%. The class of proton pump inhibitors (PPIs) has many types like esomeprazole, pantoprazole, omeprazole, rabeprazole, lansoprazole, and dexlansoprazole. This market has wide growth and competition.

Growth factors of Proton Pump Inhibitor market

Proton pump inhibitors work on decreasing the acid in the stomach. It treats stomach ulcers, symptoms of acid reflux, heartburn, and gastroesophageal reflux disease (GERD). There are main factors for growing this market :

1: The lifestyles of many people depend on spicy and oily foods which cause acid reflux and GERD. The market share of GERD was 49.7% in 2022.

2: obesity.

3: PPIs are prescribed through a prescription and they are also available over-the-counter (OTC).

4: Over 50% of people in the world are infected with Helicobacter pylori infection so the market of PPIs has grown.

Regional analysis of the proton pump inhibitors market

North America is leading in the PPIs market with a market share of 38.3% in 2024. about 18.1% to 27.8% in North America have GERD because of an unhealthy lifestyle. The major markets in North America are Mexico, Canada, and the US. Europe is the second-largest market. The UK and Germany are the countries with the largest markets in Europe. However, the fastest-growing market is Asia, with China and India as the main markets.

The most Proton pump inhibitor In the market

Omeprazole has the highest market share at 30.2% in 2024. It is considered the first proton pump inhibitor, so it is popular among patients and doctors. Also, esomeprazole is expected to achieve notable growth in the market.